[Clinical experience with the cardiac glycoside Gitoformat (author's transl)].
Gitoformat, a new derivate of Gitoxin, was tested with 50, mainly geriatic patients with a manifested cardiac insufficiency. The initial treatment as well as a changeover from the usual glycosid-treatment after a renewed decompensation was without any problems. With a rate of success of 95 per cent the efficiency of this new glycosid can be classified as excellent. Side effects or incompatibility were consequences of overdosage. It is remarkable that also patients with a reduced renal function did not need a reduction in dose. At 10 patients the recompensation with Gitoformat continued after discharge over an observation period of 6 months. The maintenance dose had not to be changed, incompatibility or overdosage reactions didn't appear.